News & events.

Our news.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News

August 12, 2026

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

News

August 11, 2026

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

News

August 10, 2026

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

News

August 7, 2026

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

News

August 5, 2026

AbCellera Reports Q2 2026 Business Results

News

July 29, 2026

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

News

July 7, 2026

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

News

July 6, 2026

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

News

June 17, 2026

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

News

June 5, 2026

AbCellera Appoints Dr. Victor Sandor to its Board of Directors